Thank you for visiting Gilead.com. Please explore this section for the latest news about Gilead, our groundbreaking research and our therapeutics.
Please see Gilead-at-a-Glance to learn more about the company and our portfolio of products.
Sign-up to receive email alerts whenever new company information is posted to the site.
Recent NewsJune 26, 2009 European CHMP Adopts Positive Opinion for Aztreonam Lysine
June 18, 2009 Gilead Sciences to Present at the Piper Jaffray 4th Annual Europe Conference on Wednesday, June 24
June 2, 2009 Gilead Sciences to Present at Two Upcoming Investor Conferences
May 28, 2009 Gilead Sciences' Marketing Authorisation Application for Regadenoson Validated by European Medicines Agency
May 22, 2009 Gilead Sciences Announces Changes to Cardiovascular R
&
D Organization Leadership
May 18, 2009 New Data for Gilead Sciences' Ambrisentan Show Clinical Improvements in a Diverse Pulmonary Hypertension (PH) Population
May 15, 2009 Gilead Sciences to Present at the Deutsche Bank 34th Annual Healthcare Conference on Tuesday, May 19
May 14, 2009 Gilead Sciences Files Second Patent Infringement Lawsuit Against Teva Pharmaceuticals
May 12, 2009 Gilead Palo Alto, Inc. Announces Tender Offer for Convertible Notes May 8, 2009 Gilead Sciences' Phase III Darusentan Data Show Significant Blood Pressure Reductions in Resistant Hypertension Patients
April 21, 2009 Gilead Sciences Announces Record First Quarter 2009 Financial Results April 17, 2009 Gilead Sciences Completes Acquisition of CV Therapeutics
April 17, 2009 Gilead Initiates Phase II Clinical Trial of Integrase-Based, Single-Tablet, Once-Daily Regimen for the Treatment of HIV
April 15, 2009 Gilead Sciences Successfully Completes Tender Offer for Shares of CV Therapeutics With Over 88 Percent of Shares Tendered April 14, 2009 Gilead Sciences to Release First Quarter 2009 Financial Results on Tuesday, April 21, 2009
April 13, 2009 Phase III Data for Gilead Sciences' Darusentan Accepted as Late-Breaker Presentation at ASH 2009
April 6, 2009 Gilead Sciences Announces Notification of ANDA Filing for Atripla(R) April 2, 2009 Phase III Study of Gilead's Darusentan for Resistant Hypertension Meets Primary Endpoints
|